Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2808-02 Phase 1 single and multiple oral dose study in healthy and elderly Japanese subjects
jRCT2071200099Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ONO-2808 in Neurodegenerative disorders (NDDs) (5 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Safety and tolerability of ONO-2808 (all parts), Pharmacokinetics of ONO-2808 (all parts) and 1 more. Started Mar 2021; status: completed.
02
Drugs
ONO-2808
03
Conditions
Neurodegenerative disorders (NDDs)
Beyond the preview
Go deeper on jRCT2071200099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200099.